Shukra Pharmaceuticals MD, chairman, board of directors and AGM
NSE: SHUKRAPHARBSE: 524632Pharmaceuticals & BiotechnologySmall Cap
Share price at the NSE close on 23 Oct 2026. Previous close ₹62.53.
- Next results date: the board meets on 3 Nov 2026 to consider: financial results.
- Market capMarket capitalisation. Share price times the number of shares: what the whole company is worth at the day's price. The rank is by average market value over the six months to Jun 2026, among listed companies.
- ₹2,834 Cr1,258th largest listed
- P/EPrice to earnings, trailing. Market cap divided by the profit of the last twelve months (the latest four quarters, or two half years for a company that reports half-yearly) that belongs to the company's own shareholders, after the share of the other owners of its subsidiaries: what investors pay for each rupee of a year's profit. The filing of 12 Aug 2026
- 78.6
- P/BPrice to book. Market cap divided by the net worth that belongs to the company's own shareholders, its assets less everything it owes and less the other owners' share of its subsidiaries, on its latest balance sheet. The filing of 15 Jul 2026
- 31.5
- Dividend yieldDividend yield. Dividends paid per share in the twelve months to the day, as a percentage of the day's share price.
- 0.02%
- ROEReturn on equity. Profit over the last twelve months (the latest four quarters, or two half years for a company that reports half-yearly) that belongs to the company's own shareholders, as a percentage of their net worth, the money they have in the business. Net worth is the average of the latest balance sheet and the one a year before it. The filing of 12 Aug 2026
- 47.2%
- ROCEReturn on capital employed. Operating profit after depreciation (revenue less operating expenses and depreciation, without other income and one-off items) as a percentage of all the money the business runs on: the whole group's net worth, the other owners of its subsidiaries included, plus borrowings. Lease liabilities are not counted: the results filings do not state them. The profit is over the last twelve months (the latest four quarters, or two half years for a company that reports half-yearly); net worth and borrowings are on the latest balance sheet. The filing of 12 Aug 2026
- 47.3%
- Debt to equityDebt to equity. Borrowings divided by the whole group's net worth, the other owners of its subsidiaries included: rupees borrowed for each rupee of equity in the business. Lease liabilities are not counted: the results filings do not state them. From the balance sheet at the end of Mar 2026. The filing of 15 Jul 2026
- 0.06
- Volume, NSEVolume. Shares traded on the last trading day; delivery is the part buyers kept rather than sold again the same day.
- 1,99,54,06817.8% delivered
Statutory auditor
Named in the results for the quarter to Mar 2026.
- M/s Shah Sanghvi & AssociatesPeer-review certificate valid to Aug 2028
A statutory auditor checks the company's accounts and signs its results. Peer review is the accountants' institute's check of an audit firm's own work, which a listed company's auditor must hold a valid certificate of.
Shukra Pharmaceuticals AGM and shareholder votes
Each resolution, how the votes went, and how institutions voted apart from the promoters. A postal ballot is a vote by post or online, held without a meeting.Shukra Pharmaceuticals dividend history
Annual general meeting, 28 Sep 2026
33,659 shareholders on the register on 21 Sep 2026; present: 3 promoters and 45 others; votes counted by Rupal Patel / Rupal Patel.The company's voting result (opens in a new tab)
- Consideration and Adoption of the Audited Financial Statements of the Company for the Financial Year ended March 31, 2026 and the Reports of the Board of Directors and Auditors thereonOrdinary100.00% for0.00% against
Against: promoters 0.00% · institutions 0.00% · other public 0.11%
Turnout: all 2.38% · promoters 4.56% · institutions 0.00% · other public 0.09%
- Approve and declare final dividend for the financial year 2025-26Ordinary100.00% for0.00% against
Against: promoters 0.00% · institutions 0.00% · other public 0.19%
Turnout: all 2.38% · promoters 4.56% · institutions 0.00% · other public 0.09%
- Re-appointment of Ms. Sanskruti Patel (DIN: 07108631) as a Director (Executive), who retires by rotation and being eligible, offers herself for re-appointmentOrdinary99.86% for0.14% against
Against: promoters 0.00% · institutions 0.00% · other public 0.14%
Turnout: all 0.04% · promoters 0.00% · institutions 0.00% · other public 0.09%
- Regularisation of appointment of Additional Independent Director Mr. Dinesh Chauhan (DIN: 11456530), as Non-Executive Independent Director of the CompanySpecial100.00% for0.00% against
Against: promoters 0.00% · institutions 0.00% · other public 0.14%
Turnout: all 2.38% · promoters 4.56% · institutions 0.00% · other public 0.09%
For and against are per cent of the votes cast. Turnout is the votes cast as a per cent of the shares each group holds. Institutions are funds, insurers, banks and foreign investors. An ordinary resolution passes with more than half the votes cast, a special one with at least three quarters.
Postal ballot, 26 Sep 2026, 2 resolutions
30,891 shareholders on the register on 21 Aug 2026; votes counted by Rupal Patel / Rupal Patel.The company's voting result (opens in a new tab)
- AMENDMENT IN OBJECT CLAUSE OF THE MEMORANDUM OF ASSOCIATION OF THE COMPANYSpecial99.97% for0.03% against
Against: promoters 0.00% · institutions 0.00% · other public 0.62%
Turnout: all 2.45% · promoters 4.56% · institutions 0.00% · other public 0.23%
- CHANGE OF NAME OF THE COMPANY FROM ‘SHUKRA PHARMACEUTICALS LIMITED’ to ‘SHUKRA MEDTECH LIMITED’ AND CONSEQUENT AMENDMENT IN MEMORANDUM AND ARTICLES OF ASSOCIATION OF THE COMPANYSpecial99.96% for0.04% against
Against: promoters 0.00% · institutions 0.00% · other public 0.66%
Turnout: all 1.93% · promoters 3.55% · institutions 0.00% · other public 0.23%
For and against are per cent of the votes cast. Turnout is the votes cast as a per cent of the shares each group holds. Institutions are funds, insurers, banks and foreign investors. An ordinary resolution passes with more than half the votes cast, a special one with at least three quarters.
How money raised was used
The company's results filing for the quarter to Jun 2026 says no statement of how money raised was used applies to it.